No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects

Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects

(2013) Stephan A. Veltkamp et al.   CLINICAL DRUG INVESTIGATION

Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus

(2011) Sherwyn L. Schwartz et al.   Diabetes Technology & Therapeutics

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

(2010) A. J. Scheen   DIABETES OBESITY & METABOLISM

Sodium-Glucose Co-Transport Inhibitors

(2010) Joshua J. Neumiller et al.   DRUGS

Glucose Control by the Kidney: An Emerging Target in Diabetes

(2009) Olivera Marsenic   AMERICAN JOURNAL OF KIDNEY DISEASES

Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)

(2009) Nancy A. Thornberry et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes

(2008) S. A. Jabbour et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE